Dilon Medical Technologies

Newport News, Virginia, USA  All United States companies → — Founded 1997
Medical Device / Hardware Specialty-Focused AI
General Surgery Oncology Pathology
Oncology AI Surgical AI
Growth Capital / Private Equity-Backed — $63M

Products

DUNE MEDICAL DEVICES MARGINPROBE SYSTEM
Dilon Medical Technologies
Oncology AI
The MarginProbe System is a non-invasive medical device that uses radiofrequency spectroscopy to provide real-time intraoperative assessment of excised breast tissue margins, helping surgeons ensure clear margins during lumpectomy and reduce re-excision rates.

See all 1 product →

About Dilon Medical Technologies

Dilon Medical Technologies Inc. is a medical device manufacturer dedicated to improving patient outcomes globally through innovative medical solutions. The company’s portfolio primarily focuses on women’s healthcare, particularly in breast cancer treatment and diagnosis, and has expanded into biosurgery. Key products include MarginProbe®, a groundbreaking technology for accurate, real-time margin assessment during breast cancer surgery, which aims to significantly reduce re-excision rates. Clinical studies have demonstrated MarginProbe’s ability to reduce repeat surgeries by 25% to 80%, with a 2025 study showing a 42% reduction for patients with ductal carcinoma in situ (DCIS).

Beyond breast cancer, Dilon offers a range of other medical devices. This includes HEMOBLAST® Bellows, an FDA-approved powdered surgical hemostat for controlling minimal, mild, and moderate bleeding in various surgical procedures, including cardiac, general, and orthopedic surgeries. The Navigator™ System is a surgical gamma probe used for radio-guided lymphatic mapping and tumor localization. Additionally, Dilon provides the TrueView Pro 100, a specimen radiography system with advanced radiography and automated software for precise identification of tumor lesions, and the CoPilot, a portable video laryngoscope for airway management. While some products utilize advanced software, the company is not explicitly identified as an ‘AI company’ in the provided information.

Focus Areas

Breast cancer treatment and diagnosis biosurgery lymphatic mapping tumor localization hemostasis airway management medical imaging

Business Intelligence

Key InvestorsCanepa Healthcare, ATON Partners, The Kraft Group, JGB Management, Bon Secours Mercy Health, Taglich Brothers, F9 Investments
PartnershipsXtant Medical (exclusive U.S. distribution rights for HEMOBLAST Bellows), GE Healthcare (distribution agreement)
AcquisitionsDune Medical Devices (MarginProbe), RMD Instruments (Navigator gamma probe business)
TechnologyRadio-frequency (RF) spectroscopy platform, radio-guided lymphatic mapping and tumor localization, advanced radiography and automated software
FDA Clearances2 cleared products (estimated)

What Physicians Need to Know

Breast Cancer Treatment & Diagnosis
Dilon Medical Technologies offers comprehensive solutions for breast cancer, including the MarginProbeu00ae system for real-time intraoperative margin assessment during lumpectomies, significantly reducing re-excision rates. They also provide the TrueViewu2122 Pro 100 for specimen radiography and the Navigatoru2122 System for lymphatic mapping and tumor localization. Their Dilon 6800u00ae Gamma Camera supports molecular breast imaging for early detection.
Biosurgery & Hemostasis
The company specializes in biosurgery with HEMOBLASTu00ae Bellows, a unique combination powdered surgical hemostat containing collagen, thrombin, and chondroitin sulfate, indicated for controlling minimal, mild, and moderate bleeding in various surgical procedures.
Lymphatic Mapping & Tumor Localization
Dilon's Navigatoru2122 System is a world-renowned surgical gamma probe used for radio-guided lymphatic mapping and precise tumor localization, crucial for various cancer surgeries.
Airway Management
They provide advanced airway management solutions with the CoPilot VL+u00ae video laryngoscope, designed for optimal airway visualization, portability, and ease of use in various medical settings.
Medical Imaging
Dilon offers medical imaging technologies like the TrueViewu2122 Pro 100 specimen radiography system for precise identification of tumor lesions, and the Dilon 6800u00ae Gamma Camera for molecular breast imaging, which aids in detecting smaller and harder-to-find cancers.
Physician Tip

For physicians, Dilon Medical Technologies stands out by offering evidence-based solutions that directly address critical surgical challenges and aim to improve patient outcomes. The MarginProbeu00ae system provides real-time, intraoperative feedback on breast cancer margins, potentially reducing the need for repeat surgeries and alleviating patient anxiety. Its patented RF technology offers high sensitivity for detecting cancerous tissue, including DCIS. The HEMOBLASTu00ae Bellows offers a unique and effective solution for surgical hemostasis, simplifying bleeding control. The Navigatoru2122 System's wireless, calibration-free design enhances OR efficiency and flexibility for lymphatic mapping and tumor localization. Furthermore, the portable and user-friendly CoPilot VL+u00ae video laryngoscope aims to make optimal airway visualization a standard of care. Dilon's commitment to innovation and a strong portfolio of specialized devices empower surgeons with greater confidence and precision in their procedures.

While explicit details on EMR or broad hospital system integrations are not extensively highlighted, Dilon's technologies are designed for seamless integration into existing operating room workflows. For example, MarginProbeu00ae is built to integrate smoothly into the surgical process, allowing for immediate decision-making. The Navigatoru2122 System's wireless probes and lack of calibration streamline its use in the OR. The company also utilizes platforms like AcuityMD to efficiently identify and engage with physicians, suggesting an understanding of data-driven outreach and potentially future integration opportunities within healthcare IT ecosystems.

Products by Dilon Medical Technologies

1 product in the directory

DUNE MEDICAL DEVICES MARGINPROBE SYSTEM
Dilon Medical Technologies
Oncology AI
The MarginProbe System is a non-invasive medical device that uses radiofrequency spectroscopy to provide real-time intraoperative assessment of excised breast tissue margins, helping surgeons ensure clear margins during lumpectomy and reduce re-excision rates.

What the Web Says

Dilon Medical Technologies is a women's healthcare company that has expanded into biosurgery, developing and manufacturing innovative medical devices. Their product portfolio includes MarginProbe for breast cancer surgery, HEMOBLAST Bellows for surgical hemostasis, and Navigator for radio-guided surgical procedures. Employer reviews suggest a generally pleasant work environment with a small company feel.

Overall: Positive

Strengths

  • Innovative medical devices for women's healthcare and biosurgery
  • MarginProbe significantly reduces re-excision rates in breast cancer surgery
  • HEMOBLAST Bellows is the only FDA-approved powdered surgical hemostat with a specific indication for minimal, mild, and moderate bleeding
  • Employees generally find it a pleasant company to work for
  • Small company values with big company goals
  • Team-oriented work environment

Limitations

  • As a small company, job descriptions may change frequently
  • Limited number of employee reviews available
  • Some older reviews mention long shifts and poor management (though this appears to be from a different company named 'Dillion')

Based on reviews from: Indeed.com, Dilon Technologies Website, BioSpace, PR Newswire, G2, Capterra, Reddit

Last updated: 2026-07-19

Videos

News, demos, and interviews about Dilon Medical Technologies.

Loading videos...

Videos load interactively. If none appear, search YouTube for Dilon Medical Technologies →

View all on YouTube

Press & Coverage

Pulse 2.0
Dilon Technologies: $9 Million Growth Financing Raised For Biosurgery Treatment
Dilon Technologies secured $9 million in growth capital from JGB Management to support its expanding medical device portfolio, including biosurgery and breast cancer treatment technologies. This funding will help Dilon continue its double-digit growth and operational scaling.
2025-06
Medical Product Outsourcing (MPO)
FDA Approves Dilon Technologies' Intraoperative Margin Assessment Tool
Dilon Technologies announced FDA approval and U.S. launch of its MarginProbe 2 system, a next-generation device for real-time intraoperative margin assessment in breast cancer surgery. This device aims to improve precision during breast-conserving surgeries and reduce the need for repeat procedures.
2026-01
PR Newswire
Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLASTu00ae Bellows Product
Xtant Medical Holdings, Inc. and Dilon Technologies, Inc. have entered into an exclusive U.S. distribution agreement for Dilon's HEMOBLASTu00ae Bellows product, a high-performance hemostatic agent. Xtant Medical has also hired Dilon's U.S. sales team to support the distribution.
2026-04
BioSpace
Dilon Technologies Announces the Beginning of Enrollment in its Pivotal Trial of the Next Generation MarginProbeu2122 2 Used in Real-Time Margin Assessment
Dilon Technologies has begun enrolling patients in a pivotal trial for its next-generation MarginProbeu2122 2, designed for real-time margin assessment in breast cancer surgery. This trial aims to further improve patient outcomes by potentially increasing sensitivity and reducing false negatives.
2024-02
AcuityMD Press Release
Dilon Technologies selects AcuityMD platform to accelerate its preventative breast cancer surgery devices to more oncologists
Dilon Technologies partnered with AcuityMD to utilize their commercial platform to identify and engage physicians for its MarginProbeu00ae technology, which aims to reduce re-excision rates in breast cancer surgery. AcuityMD's platform helps Dilon reach more oncologists and medical facilities in need of its technology.
2022-04
Dilon Technologies
Publication of Data Demonstrating Cost-Savings Results from the Use of MarginProbeu2122 Compared to a Full Cavity Shave (FCS) Approach
Dilon Technologies announced the publication of a study in the Journal of Cost Effectiveness and Resource Allocation, demonstrating that using MarginProbeu2122 to reduce re-excisions in breast-conserving surgery can lead to cost savings compared to a full cavity shave approach.
2023-09
VC News Daily
Dilon Technologies Closes $9M in Growth Capital
Dilon Technologies, a medical device leader in biosurgery and breast cancer treatment, secured $9 million in growth capital from JGB Management Inc. This investment will support the company's continued double-digit revenue growth and operational scaling.
2025-06
Medical Device Network
FDA approves Dilon's intraoperative margin assessment device
The US Food and Drug Administration (FDA) has approved Dilon Technologies' MarginProbe 2, a next-generation intraoperative margin assessment device for breast cancer surgery. This approval enables its launch in the American market, aiming to decrease repeat procedures and improve patient outcomes.
2025-12

Frequently Asked Questions

The MarginProbe system provides real-time intraoperative margin assessment during lumpectomy procedures, helping surgeons identify cancerous cells at tissue margins. This FDA-approved technology aims to significantly reduce re-excision rates, improving patient outcomes and potentially avoiding the need for additional surgeries.
Dilon Medical Technologies provides the Navigator System, a surgical gamma probe system used for radio-guided lymphatic mapping and precise tumor localization. This system is a trusted brand globally, aiding surgeons in procedures like sentinel lymph node biopsies and is designed for low-temperature sterilization in line with healthcare standards.
Dilon offers HEMOBLAST Bellows, an FDA-approved powdered surgical hemostat containing collagen, thrombin, and chondroitin sulfate, indicated for controlling minimal, mild, and moderate bleeding in various surgical procedures. As of April 2026, Xtant Medical Holdings, Inc. has acquired exclusive U.S. distribution rights for HEMOBLAST Bellows.
Dilon's TrueView Pro 100/200 is a specimen radiography system that uses advanced radiography and automated software to precisely identify tumor lesions in resected or biopsied breast tissue. These systems are designed to improve workflow and accuracy in breast-conserving surgery, complementing Dilon's FDA-approved breast cancer technologies like MarginProbe.
Dilon Medical Technologies offers the CoPilot VL+ video laryngoscope, an innovative, portable, and easy-to-use system for airway management. It provides optimal visualization during intubation and is designed for use in various medical settings, including the operating room, intensive care unit, and emergency medical responder field.
Dilon Medical Technologies is a commercial-stage company with over 20 years in the medical device industry, operating in more than 76 countries. They secured a $9 million growth capital investment in June 2025 to support continued expansion. Dilon offers service plans and support through trained clinical and technical specialists, as demonstrated with their Canadian partners.
Dilon emphasizes the cost-effectiveness of its solutions, such as the TrueView Pro 100/200 for breast centers and the affordably priced CoPilot VL+ video laryngoscope, enabling wider access. Their MarginProbe technology also aims to reduce overall healthcare costs by significantly lowering breast cancer re-excision rates, leading to fewer follow-up procedures.

Related Companies

Google DeepMind is a leading artificial intelligence (AI) research laboratory, a subsidiary of Alphabet Inc., dedicated to developing advanced AI systems to benefit humanity. The company focuses on creating general-purpose AI that can learn and solve complex problems, drawing inspiration from neuroscience and machine learning. Their work spans various fields, including healthcare, scientific discovery, and […]

TalkToMedi is a Canadian healthcare AI company that has developed a clinical-grade voice AI platform called MEDI. This platform is designed to automate patient communication and administrative tasks for medical clinics, including family medicine, specialty clinics, allied health, and physiotherapy. MEDI handles high-volume patient calls, automating appointment inquiries, booking, rescheduling, and cancellations based on the […]

Menaela is an AI-first practice management system designed for solo practitioners, small private clinics, and clinic owners. It integrates patient communication, scheduling, CRM, and medical documentation into a single platform, aiming to replace multiple disconnected tools and bots. The system features an AI practice manager that understands natural-language requests, utilizes real clinic data, and performs […]

Avie is operated by AVIE TECNOLOGIA LTDA, headquartered in Santo André, São Paulo, Brazil. Avie provides WhatsApp reception in Brazilian Portuguese, appointment scheduling, rescheduling and cancellations through Google Calendar or Feegow, clinic CRM, follow-up messages and an online booking website. Clinic staff can review conversations and take over when human support is needed. Clinic CRM […]

Saile is a physician-founded healthcare technology company that addresses critical inefficiencies in healthcare staffing and credentialing. Their AI-powered platform acts as a “universal credential passport” for physicians, centralizing and managing all medical licenses, certifications, and CME credits in one secure, portable vault. This system aims to significantly reduce the administrative burden and delays associated with […]

Data Capture Experts (DCE) is an Australian-based healthcare AI company that is at the forefront of digital health transformation. They specialize in developing and implementing digital health platforms that integrate data, technology, and human-centered design to create intuitive and connected healthcare systems. Their flagship platform, DC2Vue, is designed to go beyond traditional Electronic Medical Records […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.